Volume 10 Issue 2
Sep.  2020
Turn off MathJax
Article Contents
Shi-qi WANG, Cheng CHI, Jie LIU. Advance in the Topical Medication and Physical Therapy for Cutaneous T Cell Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 157-161. doi: 10.3969/j.issn.1674-9081.2019.02.014
Citation: Shi-qi WANG, Cheng CHI, Jie LIU. Advance in the Topical Medication and Physical Therapy for Cutaneous T Cell Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 157-161. doi: 10.3969/j.issn.1674-9081.2019.02.014

Advance in the Topical Medication and Physical Therapy for Cutaneous T Cell Lymphoma

doi: 10.3969/j.issn.1674-9081.2019.02.014
More Information
  • Corresponding author: LIU Jie Tel:010-69151536,E-mail: Liujie04672@pumch.cn
  • Received Date: 2017-04-27
  • Publish Date: 2020-09-18
  • Cutaneous T cell lymphoma(CTCL) are mostly indolent, which slowly progress. The patients usually get a definite diagnosis in the early stage. Topical medication and physical therapy are the mainstays in the treatment of CTCL, including topical corticosteroids, immunosuppressive agents, retinoids, radiation therapy, and phototherapy. In recent years, the efficacy and safety of traditional methods has been further evaluated. Meanwhile, some new strategies of topical medication and physical therapy such as topical tazarotene, topical resiquimod, ultraviolet A plus new photosensitizer, and photodynamic therapy have been employed for CTCL. This article reviewed the research progress of topical medication and physical therapy for CTCL.
  • loading
  • [1] Talpur R, Venkatarajan S, Duvic M. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma[J]. Expert Rev Clin Pharmacol, 2014, 7:591-597. doi:  10.1586/17512433.2014.944500
    [2] 罗毅鑫, 刘洁.皮肤T细胞淋巴瘤靶向治疗的研究进展[J].临床皮肤科杂志, 2016, 45:814-817. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=lcpfkzz201611025
    [3] Nguyen CV, Bohjanen KA. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma[J]. Dermatol Clin, 2015, 33:683-696. doi:  10.1016/j.det.2015.05.004
    [4] Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids[J]. Dermatol Ther, 2003, 16:283-287. doi:  10.1111/j.1396-0296.2003.01639.x
    [5] Liu DY, Shaath T, Rajpara AN, et al. Safe and Efficacious Use of Intralesional Steroids for the Treatment of Focally Resistant Mycosis Fungoides[J]. J Drugs Dermatol, 2015, 14:466-470. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=6e5cda89b7d0ee0f68aa357c483a291e
    [6] Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides[J]. JAMA Dermatol, 2013, 149:1-8. https://www.scholars.northwestern.edu/en/publications/topical-chemotherapy-in-cutaneous-t-cell-lymphoma-positive-result
    [7] Benjamin CA, Markel K, Tawa MC. Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel[J]. Clin J Oncol Nurs, 2015, 19:E131-E139. doi:  10.1188/15.CJON.E131-E139
    [8] Lindahl LM, Fenger-Gron M, Iversen L. Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis[J]. J Eur Acad Dermatol Venereol, 2013, 27:163-168. doi:  10.1111/j.1468-3083.2011.04433.x
    [9] 单百卉, 李雪, 郑玉洁, 等.口服阿维A联合氮芥外用治疗老年蕈样肉芽肿1例[J].中国老年学, 2013, 33:1155-1156. doi:  10.3969/j.issn.1005-9202.2013.05.077
    [10] Lindahl LM, Fengergrøn M, Iversen L. Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study[J]. Br J Dermatol, 2014, 170:699-704. doi:  10.1111/bjd.12620
    [11] Apisarnthanarax N, Wood GS, Stevens SR, et al. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type[J]. Arch Dermatol, 2012, 148:613-620. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=f334ee1ba665c917e9307f107a6442a0
    [12] Macarthur KM, Jariwala N, Kim EJ, et al. Topical Carmustine as Monotherapy or as Multimodality Therapy for Folliculotropic Mycosis Fungoides[J]. Acta Derm Venereol, 2017, 97:373-374. doi:  10.2340/00015555-2551
    [13] Heisig M, Maj J, Szepietowski JC, et al. Durable remission of folliculotropic mycosis fungoides achieved with a combined topical treatment with cytarabine and carmustine[J]. Dermatol Ther, 2015, 29:15-18. http://smartsearch.nstl.gov.cn/paper_detail.html?id=abbd764765a9bcd6f5c3430610a394c2
    [14] Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study[J]. J Am Acad Dermatol, 2004, 50:600-607. doi:  10.1016/j.jaad.2003.09.005
    [15] Besner MC, Roberge D, Turchin I, et al. Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma[J]. J Cutan Med Surg, 2016, 20:244-248. doi:  10.1177/1203475415626686
    [16] Coors EA, Von d DP. Treatment of 2 patients with mycosis fungoides with alitretinoin[J]. J Am Acad Dermatol, 2012, 67:e265-e267. doi:  10.1016/j.jaad.2012.05.011
    [17] Miernik B, Schmidt V, Technau-Hafsi K, et al. Alitretinoin in the treatment of palmoplantar mycosis fungoides: a new and promising therapeutic approach[J]. Clin Exp Dermatol, 2014, 40:445-447. https://www.ncbi.nlm.nih.gov/pubmed/25476933/
    [18] Bassiri-Tehrani S, David E. Treatment of cutaneous T-cell lymphoma with alitretinoin gel[J]. Int J Dermatol, 2002, 41:104-106. doi:  10.1046/j.1365-4362.2002.01363.x
    [19] Gordon MC, Sluzevich JC, Jambusariapahlajani A. Clearance of folliculotropic and tumor mycosis fungoides with topical 5% imiquimod[J]. JAAD Case Rep, 2015, 1:348-350. doi:  10.1016/j.jdcr.2015.08.007
    [20] Rook AH, Gelfand JC, Wysocka M, et al. Topical resiqui-mod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma[J]. Blood, 2015, 126:1452.
    [21] Killock D. Haematological cancer: Resiquimod-a topical CTCL therapy[J]. Nat Rev Clin Oncol, 2015, 126:1452-1461. http://www.nature.com/nrclinonc/journal/v12/n10/full/nrclinonc.2015.142.html
    [22] Emmilia H, Lev P. Phototherapy of Mycosis Fungoides[J]. Dermatol Clin, 2015, 33:697-702. doi:  10.1016/j.det.2015.05.005
    [23] Olsen EA, Hodak E, Anderson T, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium[J]. J Am Acad Dermatol, 2016, 74:27-58. doi:  10.1016/j.jaad.2015.09.033
    [24] Koh MJ, Chong WS. Narrow-band ultraviolet B phototherapy for mycosis fungoides in children[J]. Clin Exp Dermatol, 2014, 39:474-478. doi:  10.1111/ced.12364
    [25] Hernández Z, Peñate Y, Hernándezmachín B, et al. Treat-ment of stage Ia and Ib mycosis fungoides with psoralen UVA monotherapy: an observational study in tertiary hospitals in the Canary Islands[J]. Int J Dermatol, 2014, 53:1417-1422. doi:  10.1111/ijd.12425
    [26] Pavlotsky F, Hodak E, Ben AD, et al. Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides[J]. J Am Acad Dermatol, 2014, 71:536-541. doi:  10.1016/j.jaad.2014.04.011
    [27] 闫岩, 徐晨琛, 王涛, 等.局部甲氧沙林加紫外线A治疗难治性蕈样肉芽肿皮损的初步研究[J].中华肿瘤杂志, 2015, 37:859-862. doi:  10.3760/cma.j.issn.0253-3766.2015.11.013
    [28] Biskup E, Naym DG, Gniadecki R. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase(ATR) sensitize lymphoma cells to UVA radiation[J]. J Dermatol Sci, 2016, 84:239-247. doi:  10.1016/j.jdermsci.2016.09.010
    [29] Olek-Hrab K, Silny W, Dańczak-Pazdrowska A, et al. Ultraviolet al phototherapy for mycosis fungoides[J]. Clin Exp Dermatol, 2013, 38:126-130. doi:  10.1111/ced.12001
    [30] Aydogan K, Yazici S, Balaban AS, et al. Efficacy of low-dose ultraviolet a-1 phototherapy for parapsoriasis/early-stage mycosis fungoides[J]. Photochem Photobiol, 2014, 91:873-877. doi:  10.1111/php.12253
    [31] Mofty ME, Ramadan S, Fawzy MM, et al. Broad band UVA: a possible reliable alternative to PUVA in the treatment of early-stage mycosis fungoides[J]. Photodermatol Photoimmunol Photomed, 2012, 28:274-277. doi:  10.1111/j.1600-0781.2012.00690.x
    [32] Deaver D, Cauthen A, Cohen G, et al. Excimer laser in the treatment of mycosis fungoides[J]. J Am Acad Dermatol, 2014, 70:1058-1060. doi:  10.1016/j.jaad.2014.01.915
    [33] Xu CC, Zhang T, Wang T, et al. Palliative Local Radiotherapy in the Treatment of Tumor-stage Cutaneous T-cell Lymphoma/Mycosis Fungoides[J]. Chin Med Sci J, 2014, 29:33-37. doi:  10.1016/S1001-9294(14)60021-3
    [34] Bakar Ö, Şahin S, Çetinözman F, et al. Tumor-stage mycosis fungoides of the vulva successfully treated with local low-dose radiotherapy[J]. Dermatol Ther, 2015, 28:36-39. doi:  10.1111/dth.12181
    [35] Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma(mycosis fungoides and Sezary syndrome) Part II. Prognosis, management, and future directions[J]. J Am Acad Dermatol, 2014, 70: 223, e1-e17. https://www.researchgate.net/publication/259805399_Primary_cutaneous_T-cell_lymphoma_mycosis_fungoides_and_Sezary_syndrome_Part_II_Prognosis_management_and_future_directions
    [36] Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome[J]. J Clin Oncol, 2010, 28:2365-2372. doi:  10.1200/JCO.2009.25.8301
    [37] Wagner AE, Wada D, Bowen G, et al. Mycosis fungoides: the addition of concurrent and adjuvant interferon to total skin electron beam therapy[J]. Br J Dermatol, 2013, 169:715-718. doi:  10.1111/bjd.12386
    [38] Tandberg DJ, Craciunescu O, Kelsey CR. Radiation Therapy for Cutaneous T-Cell Lymphomas[J]. Dermatol Clin, 2015, 33:703-713. doi:  10.1016/j.det.2015.05.006
    [39] Xue J, Liu C, Liu Y. Photodynamic therapy as an alternative treatment for relapsed or refractory mycosis fungoides: a systemic review[J]. Photodiagnosis Photodyn Ther, 2017, 17:87-91. doi:  10.1016/j.pdpdt.2016.11.010
    [40] Kabata Y, Shimomura Y, Matsuo Y, et al. Photodynamic therapy with intradermal application of 5-aminolevulinic acid successfully improved tumor lesions of mycosis fungoides[J]. Int J Dermatol, 2017, 56:e81-e82. doi:  10.1111/ijd.13483
    [41] Ariel H, Cristián ND, Claudia N, et al. Topical photody-namic therapy with 5-aminolevulinate for the treatment of tumor-stage mycosis fungoides: a case report[J]. Int J Dermatol, 2013, 52:1535-1537. doi:  10.1111/j.1365-4632.2011.05427.x
    [42] Rivetti N, Cananzi R, Borroni RG, et al. Effectiveness of photodynamic therapy in refractory plaque-stage mycosis fungoides associated with Bowen's disease[J]. Dermatol Ther, 2017, 30:e12474. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b26de49d65b748d96ce0737c61c788c8
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (594) PDF downloads(225) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint